secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125347
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio reports Q3 net loss $21M, cash $169.1M; files clinical study for KRRO-110, partners Novo Nordisk
--------------------------------------------------------------------------------

- Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).
- Cash and equivalents $169.1M as of Sep 30, 2024; cash runway into H2 2026.
- Submitted regulatory filing in Australia for Phase 1/2 study of KRRO-110 in AATD; first dosing expected Q1 2025.
- Announced collaboration with Novo Nordisk for up to two targets in cardiometabolic diseases; up to $530M in milestones plus royalties.
- Appointed Jeffrey Cerio as General Counsel, Katharine Knobil to Board; formed Clinical Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/0000950170-24-125347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/krro-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer